UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
______________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): June 17, 2010
Neuro – Biotech
Corp.
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
|
33-55254-42
|
87-0485310
|
||
|
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
4020
St-Ambroise, Suite 497, Montreal, Quebec Canada
|
H4C
2C7
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area
code: 438-380-9324 ext 228
M45 Mining Resources, Inc.,
1212 Redpath Crescent, Montreal
(Quebec) Canada H3G 2K1
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal
Year.
On
February 11, 2010 the Board of Directors and Shareholders of M45 Mining
Resources, Inc. (the ‘Company”) determined it to be in the best interest of the
Company that the name of the Company be modified to Neuro-Biotech
Corp. Accordingly, on February 19, 2010 the Nevada Secretary of State
filed the Certificate of Amendment amending Article First of the Company’s
Certificate of Incorporation to read as follows: The name of the Corporation is
Neuro-Biotech Corp. On June 16, 2010 FINRA approved the
abovementioned name change and such corporate action is deemed effective June
17, 2010. The Company’s trading symbol will remain MRES.
On June
15, 2010 the Company updated its Company Business Address Information on file
with the Securities and Exchange Commission to the following:
4020
St-Ambroise
Suite
497
Montreal,
Quebec H4C 2C7
Telephone:
438-380-9324 ext 222
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereto
duly authorized.
Date:
June 17, 2010
NEURO-BIOTECH
CORP.
/s/ Barry
Somervail
Barry
Somervail, Chief Executive Officer